Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years
Status:
Unknown status
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the escalation dosage of Daunorubicin and
cytarabine is effective and safety in the treatment of older adult Chinese acute myeloid
leukemia（AML） patients aged 55 to 65 years.